CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

RSPR Pharma

Status and phase: Completed; Phase 2

Conditions: Becker Muscular Dystrophy; Duchenne Muscular Dystrophy

Treatments: Drug: CRD007

Study type: Interventional

Funder types: Industry

Identifiers

NCT01540604

Cardoz-004

Details and patient eligibility

About

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

Sex: All

Ages: 2 to 11 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented diagnosis of dystrophinopathy

Exclusion criteria

• Severe functional impairment

Trial design

0 participants in 1 patient group

CRD007 10 mg tablet

Experimental group

Treatment:

Drug: CRD007